Eligobiotics provides a new approach to explore, understand, and control bacterial ecosystems both in human and animals.
Eligobiotics is a developer of antibiotics intended to treat microbiome precision and bacteria-associated diseases. The company's antibiotics combine CRISPR/Cas system with engineered phage capsids, to develop antimicrobials that are used to eradicate resistant pathogens or virulent bacteria within the human microbiome, enabling clients to get next-generation antimicrobials to treat diseases caused by superbugs.
Eligo Bioscience may be growing as it has recently raised significant capital, specifically a $30 million investment, which indicates a strong financial influx supporting its operations and research. This funding is being directed towards advancing new treatments, including an innovative acne treatment, demonstrating the company's active product development efforts. Furthermore, the successful closure of a Series B funding round for its microbiome gene-editing technology suggests confidence from investors in Eligo Bioscience's potential and strategic direction.
Co-founder
Co-Founder | 2014-01-01
CSO & Co-founder | 2014-01-01
Co-founder/CEO | 2014-06-01
Research Scientist
Domain Not Resolving
Euro
Cloudflare Hosting
Cloudflare Blocked
Coming soon
No similar companies found